MX2012002994A - Lactamas heterociclo-substituidas farmaceuticamente utiles. - Google Patents
Lactamas heterociclo-substituidas farmaceuticamente utiles.Info
- Publication number
- MX2012002994A MX2012002994A MX2012002994A MX2012002994A MX2012002994A MX 2012002994 A MX2012002994 A MX 2012002994A MX 2012002994 A MX2012002994 A MX 2012002994A MX 2012002994 A MX2012002994 A MX 2012002994A MX 2012002994 A MX2012002994 A MX 2012002994A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutically useful
- substituted lactams
- compounds
- heterocycle
- useful heterocycle
- Prior art date
Links
- 150000003951 lactams Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 108010083755 proto-oncogene proteins pim Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24180609P | 2009-09-11 | 2009-09-11 | |
| US37114710P | 2010-08-05 | 2010-08-05 | |
| PCT/US2010/048441 WO2011031979A1 (en) | 2009-09-11 | 2010-09-10 | Pharmaceutically useful heterocycle-substituted lactams |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012002994A true MX2012002994A (es) | 2012-07-17 |
Family
ID=43732815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002994A MX2012002994A (es) | 2009-09-11 | 2010-09-10 | Lactamas heterociclo-substituidas farmaceuticamente utiles. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110071115A1 (enExample) |
| EP (1) | EP2475652A1 (enExample) |
| JP (1) | JP2013504594A (enExample) |
| KR (1) | KR20120104521A (enExample) |
| CN (1) | CN102625803A (enExample) |
| AU (1) | AU2010292116A1 (enExample) |
| BR (1) | BR112012005550A2 (enExample) |
| CA (1) | CA2773854A1 (enExample) |
| IL (1) | IL218521A0 (enExample) |
| IN (1) | IN2012DN03112A (enExample) |
| MX (1) | MX2012002994A (enExample) |
| SG (1) | SG179083A1 (enExample) |
| WO (1) | WO2011031979A1 (enExample) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8329897B2 (en) | 2007-07-26 | 2012-12-11 | Vitae Pharmaceuticals, Inc. | Synthesis of inhibitors of 11β-hydroxysteroid dehydrogenase type 1 |
| AR069207A1 (es) | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
| JP5490014B2 (ja) | 2007-12-11 | 2014-05-14 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の環状尿素阻害剤 |
| TW200934490A (en) | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
| CA2712500A1 (en) | 2008-01-24 | 2009-07-30 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| CA2715290A1 (en) | 2008-02-15 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| JP5538365B2 (ja) | 2008-05-01 | 2014-07-02 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤 |
| WO2009134400A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| US8846668B2 (en) | 2008-07-25 | 2014-09-30 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| KR20110050459A (ko) | 2008-07-25 | 2011-05-13 | 비타이 파마슈티컬즈, 인코포레이티드 | 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제 |
| WO2010010150A1 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | Synthesis of inhibitors of 11beta-hydroxysteroid dehydrogenase type 1 |
| WO2010089303A1 (en) | 2009-02-04 | 2010-08-12 | Boehringer Ingelheim International Gmbh | CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1 |
| MA33216B1 (fr) | 2009-04-30 | 2012-04-02 | Boehringer Ingelheim Int | Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1 |
| JP5656986B2 (ja) | 2009-06-11 | 2015-01-21 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １，３−オキサジナン−２−オン構造に基づく１１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤 |
| US8552212B2 (en) | 2009-11-05 | 2013-10-08 | Boehringer Ingelheim International Gmbh | Chiral phosphorus ligands |
| JP2013531636A (ja) * | 2010-05-26 | 2013-08-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ２−オキソ−１，２−ジヒドロピリジン−４−イルボロン酸誘導体 |
| US8933072B2 (en) | 2010-06-16 | 2015-01-13 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
| EP2585444B1 (en) | 2010-06-25 | 2014-10-22 | Boehringer Ingelheim International GmbH | Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders |
| CA2813671A1 (en) | 2010-11-02 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
| WO2012112568A1 (en) * | 2011-02-14 | 2012-08-23 | The Broad Institute, Inc. | Small molecule inhibitors for treating parasitic infections |
| WO2012170827A2 (en) * | 2011-06-08 | 2012-12-13 | Cylene Pharmaceuticals, Inc. | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors |
| JP6057907B2 (ja) * | 2011-10-04 | 2017-01-11 | 株式会社ヤクルト本社 | チアゾリジン誘導体又はその塩を有効成分とする医薬品 |
| KR102427777B1 (ko) | 2012-06-26 | 2022-08-01 | 델 마 파마슈티컬스 | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 |
| TW201414737A (zh) * | 2012-07-13 | 2014-04-16 | 必治妥美雅史谷比公司 | 作爲激酶抑制劑之咪唑并三□甲腈 |
| US9278950B2 (en) | 2013-01-14 | 2016-03-08 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| PT2945939T (pt) | 2013-01-15 | 2020-06-08 | Incyte Holdings Corp | Compostos tiazole e piridina carboxamidas úteis como inibidores das quinases pim |
| CN105121442B (zh) * | 2013-03-28 | 2017-05-17 | 山东轩竹医药科技有限公司 | PI3K和/或mTOR抑制剂的前药 |
| KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
| PE20160532A1 (es) | 2013-08-23 | 2016-05-21 | Incyte Corp | Compuesto de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| IL271999B2 (en) | 2017-07-28 | 2025-06-01 | Nimbus Lakshmi Inc | Tyk2 inhibitors and uses thereof |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| US11071727B2 (en) | 2018-01-26 | 2021-07-27 | Northwestern University | Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors |
| US12116363B2 (en) | 2018-10-19 | 2024-10-15 | Senhwa Biosciences, Inc. | Combinations for immune-modulation in cancer treatment |
| EP3771711A1 (en) | 2019-07-29 | 2021-02-03 | Bayer Animal Health GmbH | Pyrazole derivatives for controlling arthropods |
| AU2021207804A1 (en) | 2020-01-13 | 2022-09-01 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
| WO2021222522A1 (en) | 2020-05-01 | 2021-11-04 | Gilead Sciences, Inc. | Cd73 inhibiting 2,4-dioxopyrimidine compounds |
| TW202313052A (zh) * | 2021-06-08 | 2023-04-01 | 美商邊際分析公司 | 使用經取代吡唑并嘧啶之病毒感染治療及方法 |
| KR20240097895A (ko) * | 2021-10-29 | 2024-06-27 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| CN115160341B (zh) * | 2022-07-18 | 2023-07-18 | 中国医学科学院医学实验动物研究所 | 苯并噁嗪类化合物及其药物用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998424A (en) * | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| CN1880317B (zh) * | 2002-09-04 | 2012-10-10 | 先灵公司 | 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶 |
| JP4881558B2 (ja) * | 2002-09-04 | 2012-02-22 | シェーリング コーポレイション | サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン |
| PT1807072E (pt) * | 2004-10-29 | 2009-02-16 | Lilly Co Eli | Derivados de cicloalquil lactama como inibidores de 11- beta-hidroxi-esteróide desidrogenase 1 |
| TWI421078B (zh) * | 2005-10-06 | 2014-01-01 | Merck Sharp & Dohme | 關卡激酶抑制劑及其用途 |
| AU2006304874B8 (en) * | 2005-10-21 | 2013-07-04 | Exelixis, Inc. | Pyrimidinones as casein kinase II (CK2) modulators |
| PE20080071A1 (es) * | 2006-05-22 | 2008-02-11 | Schering Corp | PIRAZOLO[1,5-a]PIRIMIDINAS |
| US7531539B2 (en) * | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| PL2526934T4 (pl) * | 2006-09-22 | 2016-09-30 | Inhibitory kinazy tyrozynowej Brutona |
-
2010
- 2010-09-10 IN IN3112DEN2012 patent/IN2012DN03112A/en unknown
- 2010-09-10 SG SG2012016929A patent/SG179083A1/en unknown
- 2010-09-10 JP JP2012528930A patent/JP2013504594A/ja active Pending
- 2010-09-10 WO PCT/US2010/048441 patent/WO2011031979A1/en not_active Ceased
- 2010-09-10 KR KR1020127009217A patent/KR20120104521A/ko not_active Withdrawn
- 2010-09-10 CN CN2010800499575A patent/CN102625803A/zh active Pending
- 2010-09-10 EP EP10816161A patent/EP2475652A1/en not_active Withdrawn
- 2010-09-10 BR BR112012005550A patent/BR112012005550A2/pt not_active IP Right Cessation
- 2010-09-10 MX MX2012002994A patent/MX2012002994A/es not_active Application Discontinuation
- 2010-09-10 AU AU2010292116A patent/AU2010292116A1/en not_active Abandoned
- 2010-09-10 US US12/879,851 patent/US20110071115A1/en not_active Abandoned
- 2010-09-10 CA CA2773854A patent/CA2773854A1/en not_active Abandoned
-
2012
- 2012-03-07 IL IL218521A patent/IL218521A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2012DN03112A (enExample) | 2015-09-18 |
| BR112012005550A2 (pt) | 2015-09-08 |
| CA2773854A1 (en) | 2011-03-17 |
| WO2011031979A1 (en) | 2011-03-17 |
| SG179083A1 (en) | 2012-04-27 |
| AU2010292116A1 (en) | 2012-05-03 |
| JP2013504594A (ja) | 2013-02-07 |
| KR20120104521A (ko) | 2012-09-21 |
| CN102625803A (zh) | 2012-08-01 |
| EP2475652A1 (en) | 2012-07-18 |
| US20110071115A1 (en) | 2011-03-24 |
| IL218521A0 (en) | 2012-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG179083A1 (en) | Pharmaceutically useful heterocycle-substituted lactams | |
| IN2012DN03217A (enExample) | ||
| IN2012DN03213A (enExample) | ||
| MX2011012369A (es) | Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa. | |
| MX2009008347A (es) | Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso. | |
| WO2012170827A3 (en) | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors | |
| MX2020009223A (es) | Anticuerpos anti-fgfr2iiib afucosilados. | |
| MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
| CA2871471C (en) | Dna-pk inhibitors | |
| MY202022A (en) | Pyrrolotriazine compounds as tam inhibitors | |
| PH12019502646A1 (en) | Pyrazole magl inhibitors | |
| MX2014011134A (es) | Compuestos de carbamato y preparacion y uso de los mismos. | |
| WO2014164704A3 (en) | Compounds and compositions for the treatment of cancer | |
| EP4230264A3 (en) | Prodrugs of fumarates and their use in treating various deseases | |
| MX2015011984A (es) | Inhibidores de bromodominio de dihidro-pirrolopiridinona. | |
| JO2788B1 (en) | Amido phenoxyendazole compounds beneficial as C-MET inhibitors | |
| WO2008128072A3 (en) | Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders | |
| MX2011014019A (es) | Derivados de diazahomoadamantano y sus metodos de uso. | |
| MX2009012228A (es) | Compuesto de triazolil aminopirimidina. | |
| MX2010003365A (es) | Derivados de tiazol para el tratamiento de cancer. | |
| MX2009011346A (es) | Tapentadol para tratamiento de dolor con artritis. | |
| EP4378535A3 (en) | Antibiotic formulations for lower back pain | |
| AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
| PH12017501122A1 (en) | Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof | |
| SG10201805890QA (en) | Compositions and methods for treatment of abnormal cell growth |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |